Beta Bionics, Inc.
BBNXNASDAQHealthcare● Active
$14.24
+$0.35(+2.49%)
Market Cap$634353553
P/E Ratio—
52W High$32.71
52W Low$8.8
Beta Bionics, Inc. (BBNX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BBNX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 21, 2026EPS Actual
-$0.49
Est. -$0.53 · +7.5%
Revenue
$0.03B
Est. $0.03B · +2.5%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 21, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 4-Quarter EPS Beat Streak
BBNX reports quarterly as a NASDAQ-listed Medical - Equipment & Services company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.46
Rev. $3.65B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.46
Rev. Est.$3.65B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | -$0.62 | — | — | — | $0.03B | — |
| ▲ Q2 FY2026 | Apr 21, 2026 | -$0.53 | -$0.49 | +7.5% | $0.03B | $0.03B | +2.5% |
| ▲ Q1 FY2026 | Feb 17, 2026 | -$0.42 | -$0.30 | +28.6% | $0.03B | $0.03B | +5.7% |
| ▲ Q4 FY2025 | Oct 28, 2025 | -$0.45 | -$0.33 | +26.7% | $0.03B | $0.03B | -5.7% |
| ▲ Q3 FY2025 | Jul 29, 2025 | -$0.51 | -$0.39 | +23.5% | $0.02B | $0.02B | +6.1% |
| ▼ Q2 FY2025 | May 6, 2025 | -$0.51 | -$0.52 | -2.0% | $0.02B | $0.02B | -10.4% |
| ▼ Q1 FY2025 | Mar 25, 2025 | -$0.42 | -$1.82 | -333.3% | $0.02B | $0.02B | +26.6% |
| — Q1 FY2025 | Jan 31, 2025 | — | -$1.55 | — | $0.02B | — | — |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
-$0.62
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 21, 2026Beat
EPS Actual
-$0.49
EPS Est.
-$0.53
EPS Surpr.
+7.5%
Revenue
$0.03B
Q1 FY2026
Feb 17, 2026Beat
EPS Actual
-$0.30
EPS Est.
-$0.42
EPS Surpr.
+28.6%
Revenue
$0.03B
Q4 FY2025
Oct 28, 2025Beat
EPS Actual
-$0.33
EPS Est.
-$0.45
EPS Surpr.
+26.7%
Revenue
$0.03B
Q3 FY2025
Jul 29, 2025Beat
EPS Actual
-$0.39
EPS Est.
-$0.51
EPS Surpr.
+23.5%
Revenue
$0.02B
Q2 FY2025
May 6, 2025Miss
EPS Actual
-$0.52
EPS Est.
-$0.51
EPS Surpr.
-2.0%
Revenue
$0.02B
Q1 FY2025
Mar 25, 2025Miss
EPS Actual
-$1.82
EPS Est.
-$0.42
EPS Surpr.
-333.3%
Revenue
$0.02B
Q1 FY2025
Jan 31, 2025
EPS Actual
-$1.55
EPS Est.
—
EPS Surpr.
—
Revenue
$0.02B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.26 | $-0.25 | $-0.24 | 1 |
| Q3 FY2028 | $-0.29 | $-0.28 | $-0.27 | 1 |
| Q2 FY2028 | $-0.35 | $-0.34 | $-0.32 | 1 |
| Q1 FY2028 | $-0.40 | $-0.39 | $-0.37 | 1 |
| Q4 FY2027 | $-0.54 | $-0.53 | $-0.50 | 1 |
| Q3 FY2027 | $-0.52 | $-0.50 | $-0.48 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.1B | $0.1B | $0.1B | 4 |
| Q3 FY2028 | $0.1B | $0.1B | $0.1B | 4 |
| Q2 FY2028 | $0.1B | $0.1B | $0.1B | 5 |
| Q1 FY2028 | $0.0B | $0.1B | $0.1B | 2 |
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 21, 2026 | +7.5% | $12.91 | $12.27 | -4.96% |
| ▲ Q1 FY2026 | Feb 17, 2026 | +28.6% | $13.94 | $13.97 | +0.22% |
| ▲ Q4 FY2025 | Oct 28, 2025 | +26.7% | $23.75 | $24.28 | +2.23% |
| ▲ Q3 FY2025 | Jul 29, 2025 | +23.5% | $13.99 | $14.66 | +4.79% |
| ▼ Q2 FY2025 | May 6, 2025 | -2.0% | $11.68 | $11.35 | -2.83% |
| ▼ Q1 FY2025 | Mar 25, 2025 | -333.3% | $14.85 | $15.22 | +2.49% |
| — Q1 FY2025 | Jan 31, 2025 | — | $23.63 | $23.81 | +0.76% |
| — Q4 FY2023 | Dec 31, 2023 | — | No price data | $23.63 | — |
Q2 FY2026-4.96%
Report Date
Apr 21, 2026
EPS Beat/Miss
+7.5%
Price Before
$12.91
Price After
$12.27
Q1 FY2026+0.22%
Report Date
Feb 17, 2026
EPS Beat/Miss
+28.6%
Price Before
$13.94
Price After
$13.97
Q4 FY2025+2.23%
Report Date
Oct 28, 2025
EPS Beat/Miss
+26.7%
Price Before
$23.75
Price After
$24.28
Q3 FY2025+4.79%
Report Date
Jul 29, 2025
EPS Beat/Miss
+23.5%
Price Before
$13.99
Price After
$14.66
Q2 FY2025-2.83%
Report Date
May 6, 2025
EPS Beat/Miss
-2.0%
Price Before
$11.68
Price After
$11.35
Q1 FY2025+2.49%
Report Date
Mar 25, 2025
EPS Beat/Miss
-333.3%
Price Before
$14.85
Price After
$15.22
Q1 FY2025+0.76%
Report Date
Jan 31, 2025
EPS Beat/Miss
—
Price Before
$23.63
Price After
$23.81
Q4 FY2023—
Report Date
Dec 31, 2023
EPS Beat/Miss
—
Price Before
—
Price After
$23.63
Avg Beat Reaction+0.57%
Avg Miss Reaction-0.17%
Beat Rate4 / 8 quarters
Largest Move-4.96% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BBNX ends December
Beta Bionics, Inc. (BBNX) most recently reported earnings on April 21, 2026 for Q2 FY2026, posting EPS of $-0.49 — beating the analyst consensus of $-0.53 by +7.5%. BBNX has beaten EPS estimates for 4 consecutive quarters. The next BBNX earnings date is expected around September 1, 2026.
Each quarter, investors track BBNX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BBNX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BBNX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BBNX earnings · 5 questionsBeta Bionics, Inc.'s next earnings report is expected around September 1, 2026. BBNX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BBNX historically reports after market close (AMC).
BBNX earnings datewhen is BBNX earningsBBNX next earnings datewhen does BBNX report earningsBBNX earnings calendar
▸ Source: FMP · Beta Bionics, Inc. SEC filings · US GAAP · Beta Bionics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026